Teva Pharmaceutical Industries (TEVA +0.24%) is an interesting investment story. For the right investor, it could be an attractive buy. For me, however, it isn't. Here's the oppor ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

IHE has an attractive mix of high-growth stocks and cheaply valued ones. Click here to find out why IHE stock is a Buy.

Axsome Therapeutics has begun the Phase 3 CLARITY trial of solriamfetol in adults with major depressive disorder and excessive daytime sleepiness. The study focuses on a patient group that currently ...

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

Fielded among 104 U.S. rheumatologists in January 2026, the study indicates that nearly half are already aware of the upcoming FDA decision. Unaided, Sotyktu is the most frequently cited pipeline ...

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for ...

Q4 2025 earnings call recap: 2026 revenue/EBITDA/EPS guidance, CREXONT growth, biosimilars & GLP-1 updates—read key takeaways.

Pfizer Inc. (NYSE: PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full ...

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...

A rise in tuberculosis cases in Malaysia triggered social media posts falsely claiming that the bacteria responsible for the disease were deliberately inserted into Pfizer's Comirnaty Covid-19 ...